<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928187</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS12169 2LADY</org_study_id>
    <nct_id>NCT00928187</nct_id>
  </id_info>
  <brief_title>Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)</brief_title>
  <acronym>2LADY</acronym>
  <official_title>Multicentric, Non-inferiority, Randomized, Non-blinded Phase 3 Trial Comparing Virological Response at 48 Weeks of 3 Antiretroviral Treatment Regimens in HIV-1-infected Patients With Treatment Failure After 1st Line Antiretroviral Therapy (Cameroon, Burkina Faso, Senegal)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the first line antiretroviral (ARV) treatment is now largely accessible in the
      Sub-Saharian Africa countries, documentation of virological failure, drug resistance patterns
      and second line treatment evaluation are still to be consolidated in settings where viral
      load monitoring is not available and non-B HIV subtype is predominant.

      This trial aims at evaluating the efficacy and tolerance of 3 different second line treatment
      strategies: two recommended by WHO combine two non-nucleoside reverse transcriptase inhibitor
      associated with a ritonavir boosted protease inhibitor
      (emtricitabine-tenofovir-lopinavir/ritonavir and abacavir-didanosine-lopinavir/ritonavir);
      the third strategy combines emtricitabine-tenofovir-darunavir/ritonavir and is not yet
      evaluated in Sub-Saharian Africa. Darunavir has a potentially superior antiviral efficacy, a
      better tolerance and its single daily administration may facilitate treatment adherence.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Plasma HIV RNA &lt; 50 Copies/mL</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With WHO Stage 3 and 4 HIV Related Events</measure>
    <time_frame>between baseline and 48 weeks</time_frame>
    <description>patients having a diagnosis of HIV related event classified as stage 3 or 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Plasma HIV RNA &lt; 200 Copies/ml</measure>
    <time_frame>48 weeks</time_frame>
    <description>number of patients with plasma HIV RNA below 200 copies/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gain in CD4 Cells Between Baseline and W48</measure>
    <time_frame>between baseline and 48 weeks</time_frame>
    <description>median gain in circulating CD4 cells between baseline and W48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Discontinuing Study Treatment</measure>
    <time_frame>between baseline and W48</time_frame>
    <description>number of patients discounting treatment because of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance: Gastrointestinal Complains</measure>
    <time_frame>between baseline and 48 weeks</time_frame>
    <description>Gastrointestinal complaints (grade 1 to 4) between baseline and W48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance: Neuropathies (Grade 1 to 4)</measure>
    <time_frame>between baseline and W48</time_frame>
    <description>any symptom of peripheral neuropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance: Equal or Superior to a 25% Reduction in eGFR (Glomerular Filtration Rate)</measure>
    <time_frame>between baseline and W48</time_frame>
    <description>evaluation of estimated glomerular filtration rate and number of participant with a decrease equal or superior to 25% of the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>between baseline and W48</time_frame>
    <description>number of patients in different categories of adherence as measured by questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Resistance Mutations</measure>
    <time_frame>between W12 and W48</time_frame>
    <description>number of patients with resistance mutations after second line treatment failure (HIV RNA&gt; 1000 copies/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Metabolic Syndrome</measure>
    <time_frame>from baseline to week 48</time_frame>
    <description>number of patients developing metabolic syndrome over a period of 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With HIV Plasma Viral Load &lt; 50 Copies/ml</measure>
    <time_frame>Week 24</time_frame>
    <description>Snapshot of patients with HIV viral load less then 50 copies/ml at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With HIV Plasma Viral Load &lt; 200 Copies/ml</measure>
    <time_frame>Week 24</time_frame>
    <description>number of patients having a plasma viral load below 200 copies/ml at week 24</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">454</enrollment>
  <condition>HIV</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)</intervention_name>
    <description>Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)</intervention_name>
    <description>Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight &lt; 60 kg, 400 mg if weight &gt; 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)</intervention_name>
    <description>Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food</description>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over the age of 18 years at pre-inclusion and monitored under outpatient
             conditions

          -  Documented HIV-1 infection regardless of clinical stage and CD4 lymphocyte count

          -  Patient with treatment failure after first-line antiretroviral treatment with a
             combination including a non-nucleoside reverse transcriptase inhibitor and two
             nucleoside reverse transcriptase inhibitors, failure being defined as 2 measurements
             (at 1 month interval) of plasma HIV RNA levels &gt; 1000 copies/ml after at least 6
             months of uninterrupted treatment

          -  Adherence (&gt; 80%) to first- line antiretroviral treatment (questionnaire) at pre
             inclusion

          -  Patient agrees not to take any concomitant medication during the trial without
             informing the investigator

          -  Informed consent signed no later than D-15

          -  For women in childbearing age: negative pregnancy test at inclusion, with no plan of
             pregnancy in the coming 12 months and agreeing to use mechanical contraception (with
             or without hormonal contraception) during the study

        Exclusion Criteria:

          -  Infection with HIV-2 or HIV-1 groups O or N or HIV1+2

          -  Deficiency of the patient, making it difficult, if not impossible, for him/her to take
             part in the trial or understand the information provided to him/her

          -  Participation in any other clinical trial

          -  Presence of an uncontrolled, ongoing opportunistic infection or of any severe or
             progressive disease

          -  First-line treatment with a protease inhibitor, abacavir, tenofovir or ddI

          -  Ongoing treatment with rifampicin

          -  Severe hepatic insufficiency (TP &lt; 50%)

          -  ALAT &gt; 3 x ULN

          -  Creatinine clearance calculated by Cockcroft formula &lt; 50 ml/min

          -  Hb ≤ 8 g/dl

          -  Platelets &lt; 50,000 cells/mm3

          -  Neutrophiles &lt; 500 cells/ mm3

          -  Use of drugs prohibited in the context of this trial (drugs contraindicated by the SCP
             of the trial drugs) - in the event of tuberculosis or malaria during the trial, a list
             of authorized medicines and, if necessary, a dose adjustment of the antiretroviral
             medication will be provided

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sinata Koulla Shiro, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infectious diseases department, Central Hospital, Yaounde, Cameroon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Papa Salif Sow, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infectious Diseases Department, Fann Hospital, Dakar, Senegal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adrien Sawadogo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Day Hospital, CHU Sanou Souro, Bobo Dioulasso, Burkina Faso</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Day Hospital, CHU Sanou Souro</name>
      <address>
        <city>Bobo Dioulasso</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Day Hospital, Central Hospital</name>
      <address>
        <city>Yaounde</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research and Training Center, Fann Hospital</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Cameroon</country>
    <country>Senegal</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <results_first_submitted>July 11, 2016</results_first_submitted>
  <results_first_submitted_qc>September 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 8, 2016</results_first_posted>
  <last_update_submitted>January 12, 2017</last_update_submitted>
  <last_update_submitted_qc>January 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Second line treatment</keyword>
  <keyword>WHO recommendations</keyword>
  <keyword>Africa</keyword>
  <keyword>Treatment strategies</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Didanosine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment in three study sites (Yaoundé, Dakar and Bobo Dioulasso) in HIV day care clinics from January 2010 to September 2012.</recruitment_details>
      <pre_assignment_details>584 patients assessed for eligibility, 130 excluded primary (13.9%) because control viral load decreased below 1000 copies/mL after adherence support.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A</title>
          <description>emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening</description>
        </group>
        <group group_id="P2">
          <title>Arm B</title>
          <description>abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line): Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight &lt; 60 kg, 400 mg if weight &gt; 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening</description>
        </group>
        <group group_id="P3">
          <title>Arm C</title>
          <description>emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="147"/>
                <participants group_id="P3" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Analysed</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="145"/>
                <participants group_id="P3" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="141"/>
                <participants group_id="P3" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A</title>
          <description>emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening</description>
        </group>
        <group group_id="B2">
          <title>Arm B</title>
          <description>abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line): Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight &lt; 60 kg, 400 mg if weight &gt; 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening</description>
        </group>
        <group group_id="B3">
          <title>Arm C</title>
          <description>emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="152"/>
            <count group_id="B2" value="145"/>
            <count group_id="B3" value="154"/>
            <count group_id="B4" value="451"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="34" upper_limit="45"/>
                    <measurement group_id="B2" value="38" lower_limit="33" upper_limit="47"/>
                    <measurement group_id="B3" value="36" lower_limit="32" upper_limit="45"/>
                    <measurement group_id="B4" value="38" lower_limit="32" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="324"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Cameroon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burkina Faso</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Senegal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV RNA Viral Load</title>
          <units>log10 (copies/ml)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.4" lower_limit="4.0" upper_limit="5.0"/>
                    <measurement group_id="B2" value="4.6" lower_limit="4.1" upper_limit="5.1"/>
                    <measurement group_id="B3" value="4.5" lower_limit="4.0" upper_limit="5.1"/>
                    <measurement group_id="B4" value="4.5" lower_limit="4.0" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Resistance to the three first-line drugs</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 cells count</title>
          <units>cells/mm3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="199" lower_limit="92" upper_limit="318"/>
                    <measurement group_id="B2" value="195" lower_limit="100" upper_limit="288"/>
                    <measurement group_id="B3" value="153" lower_limit="81" upper_limit="261"/>
                    <measurement group_id="B4" value="183" lower_limit="87" upper_limit="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Plasma HIV RNA &lt; 50 Copies/mL</title>
        <time_frame>48 weeks</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line): Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight &lt; 60 kg, 400 mg if weight &gt; 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Plasma HIV RNA &lt; 50 Copies/mL</title>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Hypothesizing 80% efficacy at the 50 copies/mL Viral Load (VL) threshold in the control group at W48, we calculated a required sample size of 150 participants per group to show non-inferiority of ABC/ddI and DRV groups compared with control group in ITT analysis, with a non-inferiority margin of 15%, a power of 90% and a two-sided α of 5%.</non_inferiority_desc>
            <param_type>differences in proportions</param_type>
            <param_value>5.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.1</ci_lower_limit>
            <ci_upper_limit>16.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Hypothesizing 80% efficacy at the 50 copies/mL VL threshold in the control group at W48, we calculated a required sample size of 150 participants per group to show non-inferiority of ABC/ddI and DRV groups compared with control group in ITT analysis, with a non-inferiority margin of 15%, a power of 90% and a two-sided α of 5%.</non_inferiority_desc>
            <param_type>difference in proportions</param_type>
            <param_value>6.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>16.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With WHO Stage 3 and 4 HIV Related Events</title>
        <description>patients having a diagnosis of HIV related event classified as stage 3 or 4</description>
        <time_frame>between baseline and 48 weeks</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line): Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight &lt; 60 kg, 400 mg if weight &gt; 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With WHO Stage 3 and 4 HIV Related Events</title>
          <description>patients having a diagnosis of HIV related event classified as stage 3 or 4</description>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Plasma HIV RNA &lt; 200 Copies/ml</title>
        <description>number of patients with plasma HIV RNA below 200 copies/ml</description>
        <time_frame>48 weeks</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line): Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight &lt; 60 kg, 400 mg if weight &gt; 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Plasma HIV RNA &lt; 200 Copies/ml</title>
          <description>number of patients with plasma HIV RNA below 200 copies/ml</description>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="118"/>
                    <measurement group_id="O3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gain in CD4 Cells Between Baseline and W48</title>
        <description>median gain in circulating CD4 cells between baseline and W48</description>
        <time_frame>between baseline and 48 weeks</time_frame>
        <population>ITT with data available</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line): Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight &lt; 60 kg, 400 mg if weight &gt; 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food</description>
          </group>
        </group_list>
        <measure>
          <title>Gain in CD4 Cells Between Baseline and W48</title>
          <description>median gain in circulating CD4 cells between baseline and W48</description>
          <population>ITT with data available</population>
          <units>cell/mm3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133" lower_limit="82" upper_limit="220"/>
                    <measurement group_id="O2" value="136" lower_limit="78" upper_limit="206"/>
                    <measurement group_id="O3" value="115" lower_limit="58" upper_limit="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Discontinuing Study Treatment</title>
        <description>number of patients discounting treatment because of adverse events</description>
        <time_frame>between baseline and W48</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line): Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight &lt; 60 kg, 400 mg if weight &gt; 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Discontinuing Study Treatment</title>
          <description>number of patients discounting treatment because of adverse events</description>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerance: Gastrointestinal Complains</title>
        <description>Gastrointestinal complaints (grade 1 to 4) between baseline and W48.</description>
        <time_frame>between baseline and 48 weeks</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line): Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight &lt; 60 kg, 400 mg if weight &gt; 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerance: Gastrointestinal Complains</title>
          <description>Gastrointestinal complaints (grade 1 to 4) between baseline and W48.</description>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerance: Neuropathies (Grade 1 to 4)</title>
        <description>any symptom of peripheral neuropathy</description>
        <time_frame>between baseline and W48</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line): Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight &lt; 60 kg, 400 mg if weight &gt; 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerance: Neuropathies (Grade 1 to 4)</title>
          <description>any symptom of peripheral neuropathy</description>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerance: Equal or Superior to a 25% Reduction in eGFR (Glomerular Filtration Rate)</title>
        <description>evaluation of estimated glomerular filtration rate and number of participant with a decrease equal or superior to 25% of the baseline value</description>
        <time_frame>between baseline and W48</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line): Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight &lt; 60 kg, 400 mg if weight &gt; 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerance: Equal or Superior to a 25% Reduction in eGFR (Glomerular Filtration Rate)</title>
          <description>evaluation of estimated glomerular filtration rate and number of participant with a decrease equal or superior to 25% of the baseline value</description>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adherence</title>
        <description>number of patients in different categories of adherence as measured by questionnaire</description>
        <time_frame>between baseline and W48</time_frame>
        <population>patients with data available</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line): Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight &lt; 60 kg, 400 mg if weight &gt; 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence</title>
          <description>number of patients in different categories of adherence as measured by questionnaire</description>
          <population>patients with data available</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Always above 95%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least once 80-95%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least once &lt; 80%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Resistance Mutations</title>
        <description>number of patients with resistance mutations after second line treatment failure (HIV RNA&gt; 1000 copies/ml)</description>
        <time_frame>between W12 and W48</time_frame>
        <population>patients who failed second line (2 HIV RNA measure above 1000 copies/ml)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line): Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight &lt; 60 kg, 400 mg if weight &gt; 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Resistance Mutations</title>
          <description>number of patients with resistance mutations after second line treatment failure (HIV RNA&gt; 1000 copies/ml)</description>
          <population>patients who failed second line (2 HIV RNA measure above 1000 copies/ml)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Metabolic Syndrome</title>
        <description>number of patients developing metabolic syndrome over a period of 48 weeks</description>
        <time_frame>from baseline to week 48</time_frame>
        <population>population with data available</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line): Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight &lt; 60 kg, 400 mg if weight &gt; 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Metabolic Syndrome</title>
          <description>number of patients developing metabolic syndrome over a period of 48 weeks</description>
          <population>population with data available</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With HIV Plasma Viral Load &lt; 50 Copies/ml</title>
        <description>Snapshot of patients with HIV viral load less then 50 copies/ml at week 24</description>
        <time_frame>Week 24</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line): Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight &lt; 60 kg, 400 mg if weight &gt; 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With HIV Plasma Viral Load &lt; 50 Copies/ml</title>
          <description>Snapshot of patients with HIV viral load less then 50 copies/ml at week 24</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With HIV Plasma Viral Load &lt; 200 Copies/ml</title>
        <description>number of patients having a plasma viral load below 200 copies/ml at week 24</description>
        <time_frame>Week 24</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line): Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight &lt; 60 kg, 400 mg if weight &gt; 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening</description>
          </group>
          <group group_id="O3">
            <title>Arm C</title>
            <description>emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With HIV Plasma Viral Load &lt; 200 Copies/ml</title>
          <description>number of patients having a plasma viral load below 200 copies/ml at week 24</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="117"/>
                    <measurement group_id="O3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 Weeks</time_frame>
      <desc>SAE grade 3, grade 4 and hospitalisation</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A</title>
          <description>emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening</description>
        </group>
        <group group_id="E2">
          <title>Arm B</title>
          <description>abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line): Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight &lt; 60 kg, 400 mg if weight &gt; 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening</description>
        </group>
        <group group_id="E3">
          <title>Arm C</title>
          <description>emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation): Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CIM 10</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute posthemorrhagic anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Other anaemias</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Unspecified diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other functional intestinal disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Other noninfective gastroenteritis and colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal and pelvic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Abnormal findings on diagnostic imaging of lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Abnormal serum enzyme levels</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Abnormalities of breathing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Elevated blood glucose level</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Fever of other and unknown origin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Malaise and fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pain in throat and chest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Symptoms and signs concerning food and fluid intake</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Unattended death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious gastroenteritis and colitis, unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Other septicaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Respiratory tuberculosis, bacteriologically and histologically confirmed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Respiratory tuberculosis, not confirmed bacteriologically or histologically</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Tuberculosis of other organs</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Unspecified malaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intracranial injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Medical observation and evaluation for suspected diseases and conditions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Unspecified severe protein- calorie malnutrition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Volume depletion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm of liver and intrahepatic bile ducts</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Other abnormal products of conception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Spontaneous abortion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Acute tubulo-interstitial nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Other disorders of urinary system</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Unspecified renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Excessive, frequent and irregular menstruation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Salpingitis and oophoritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Bacterial pneumonia, not elsewhere classified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pneumonia in diseases classified elsewhere</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pneumonia, organism unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Respiratory failure, not elsewhere classified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cutaneous abscess, furuncle and carbuncle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Lichen simplex chronicus and prurigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CIM10</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="118" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="152"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="145"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other functional intestinal disorders</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="152"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="145"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Other noninfective gastroenteritis and colitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="152"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal and pelvic pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="145"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="152"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="145"/>
                <counts group_id="E3" events="21" subjects_affected="16" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Fever of other and unknown origin</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="145"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="152"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="145"/>
                <counts group_id="E3" events="19" subjects_affected="16" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Malaise and fatigue</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="152"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="145"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Nausea and vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="145"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pain, not elsewhere classified</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="145"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Symptoms and signs concerning food and fluid intake</sub_title>
                <counts group_id="E1" events="37" subjects_affected="28" subjects_at_risk="152"/>
                <counts group_id="E2" events="28" subjects_affected="24" subjects_at_risk="145"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E2" events="18" subjects_affected="12" subjects_at_risk="145"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Infectious gastroenteritis and colitis, unspecified</sub_title>
                <counts group_id="E1" events="37" subjects_affected="33" subjects_at_risk="152"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="145"/>
                <counts group_id="E3" events="14" subjects_affected="10" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Unspecified malaria</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="152"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="145"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contraceptive management</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="152"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="145"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pregnancy examination and test</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="152"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="145"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dorsalgia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="152"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Other joint disorders, not elsewhere classified</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="152"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="145"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Other polyneuropathies</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="152"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="145"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Other inflammation of vagina and vulva</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="145"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute bronchitis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="152"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="145"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Acute nasopharyngitis [common cold]</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="145"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Influenza, virus not identified</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="152"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="145"/>
                <counts group_id="E3" events="19" subjects_affected="16" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cutaneous abscess, furuncle and carbuncle</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="152"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="145"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Lichen simplex chronicus and prurigo</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="152"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="145"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="152"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="145"/>
                <counts group_id="E3" events="22" subjects_affected="18" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations: open label design, random imbalance at baseline. Non-inferiority not shown, results influenced by the hypothesis of 80% viral success (50 copies/mL), not reached (69% in the control group). Therefore, the study power was reduced (80%).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Laura Ciaffi</name_or_title>
      <organization>UMI 233 IRD Montpellier</organization>
      <phone>00237 694926786</phone>
      <email>lauraciaffi2002@yahoo.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

